Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
New therapeutic target offers a promising pathway for MS treatment
July 29, 2024
Researchers have identified a potential therapeutic target for the treatment of multiple sclerosis. In their latest study, which was conducted using an experimental mouse model of MS, they explored the role of connexin 43, a protein involved in cellular communication and cardiac function, and examined whether targeting this protein with specific blockers could improve MS symptoms.
In a 2013 study, researchers from Kyushu University, found that the production of Cx43 was increased in supportive cells called astroglia, near MS lesions. Cx43 is essential for cell-to-cell signaling and plays a key role in modulating the immune system. The researchers therefore hypothesized Cx43 could play a pivotal role in promoting neuroinflammation — a process where the immune response is triggered to fight off infection or heal damaged tissue — in the context of MS, ultimately leading to demyelination.
A new study by Kyushu University researchers, in collaboration with researchers from the International University of Health and Welfare, adds further support to the hypothesis that Cx43 plays a key role in causing MS. The study revealed a drug called INI-0602, which effectively ‘plugs’ and blocks Cx43 channels, markedly improved MS symptoms in mice. The researchers conducted an extensive series of experiments in an experimental mouse model of MS and in cultured astroglia cells from the mouse model, to understand the effects of Cx43 blockade. The results of these tests and analyses were consistent, suggesting that INI-0602 could not only suppress the overproduction of Cx43 in astroglia, but also mitigate many of the hallmark features of MS, including demyelination and excessive immune cell infiltration into the nervous system.
By delving further into the mechanisms underlying these results, the team found that INI-0602 led to improved symptoms by regulating immune processes. More specifically, treatment with this compound reduced the levels of proinflammatory cytokines — proteins produced by immune cells that trigger the immune system — and increased those of anti-inflammatory cytokines in the cerebrospinal fluid. The drug also altered calcium signaling in astroglia, limiting their ability to promote inflammation. Together, these effects reduced disease severity in the experimental mouse model.
The researchers said targeting Cx43 channels with specific blockers such as INI-0602 could serve as a novel therapeutic strategy for MS. This, in turn, could facilitate the development of new treatments for patients with MS. Their findings also challenge a critical issue in MS treatment, that of limiting disease progression by targeting Cx43, where current treatments are found to be less effective.
Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, researchers plan to conduct clinical trials in the future to evaluate the safety and efficacy of INI-0602 in human patients with MS. Additionally, they also plan to look at the molecular mechanisms of Cx43 in influencing neuroinflammation and demyelination in detail.
The study was published in the journal
Scientific Reports
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more